Standard Dalteparin Dosing Guidelines
Dalteparin (Fragmin) dosing varies by indication. For deep vein thrombosis (DVT) prophylaxis in abdominal surgery, adults receive 2,500 IU subcutaneously once daily, starting 1-2 hours pre-surgery and continuing for 5-10 days. For treatment of acute DVT or pulmonary embolism, it's 200 IU/kg (max 18,000 IU) daily or 100 IU/kg twice daily for at least 5 days.[1][2]
Adjustments for Renal Impairment
In patients with creatinine clearance (CrCl) <30 mL/min, fixed dosing risks accumulation due to dalteparin's renal clearance. Guidelines recommend avoiding it or using half the dose (e.g., 5,000 IU once daily for prophylaxis instead of 10,000 IU), with anti-Xa monitoring to target 0.5-1.0 IU/mL for treatment or 0.2-0.4 IU/mL for prophylaxis. Dose reductions of 25-50% are common based on levels.[1][3]
Anti-Xa Monitoring for Optimization
Therapeutic drug monitoring via anti-Xa levels is key for optimization, especially in obesity, pregnancy, extremes of body weight, or renal/hepatic issues. Measure 4 hours post-dose:
- Treatment: Adjust to 0.5-1.0 IU/mL (increase by 2,500 IU if low; decrease by 2,500 IU if high).
- Prophylaxis: Target 0.2-0.4 IU/mL.
Studies show this reduces bleeding risk by 30-50% in high-risk patients without compromising efficacy.[2][4]
Weight-Based Dosing in Special Populations
- Obesity (BMI >40): Use actual body weight up to 190 kg for 200 IU/kg daily; cap at 18,000 IU. Some protocols switch to 100 IU/kg twice daily if levels exceed target.[3]
- **Underweight (<50 kg)**: Reduce to 150 IU/kg daily to avoid supratherapeutic levels.
- Pregnancy: Titrate with anti-Xa (target 0.6-1.0 IU/mL peak), starting at 250 IU/kg daily, as volume of distribution increases.[1][4]
Evidence from registries indicates weight-based adjustments cut recurrence by 20% in VTE treatment.[2]
Extended Therapy and Cancer-Associated Thrombosis
For cancer patients, optimize at 200 IU/kg daily (max 18,000 IU) for 1 month, then 150 IU/kg daily. Monitor anti-Xa monthly; reduce by 2,500 IU if >1.1 IU/mL. Trials like CLOT show this sustains efficacy with lower bleeding than warfarin.[1][2]
Risks of Over- or Under-Dosing
Overdosing raises major bleeding risk (3-5% incidence); antidotes include protamine (partial reversal). Underdosing increases thrombosis recurrence (up to 15%). Pharmacodynamic studies emphasize individualized monitoring over fixed doses.[3][4]
[1]: FDA Fragmin Label
[2]: UpToDate: Dalteparin Dosing
[3]: American Society of Hematology 2018 Guidelines for VTE
[4]: Chest Guidelines 2012: Antithrombotic Therapy